fda compounding glp-1 enforcement news The is proposing the removal of three drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday FDA and Novo Nordisk Warned

No patient should begin GLP-1 therapy without provider evaluation and ongoing monitoring

Timing Baseline Marker A1c Why it matters Shows the longer-term blood sugar pattern that may matter during fat-loss or metabolic protocols

doi: 10.1210/jc.2011-1256

I've realised that I've had such a bad relationship with food but not any more :) You have to put the work in and commit to it but I just know this is going to change my life

Compared with GLP-1 RAs, more participants receiving tirzepatide 15 mg discontinued treatment due to adverse events (OR 2.29 [95% CI 1.39, 3.75], I 2 0%), whereas no difference was evident for tirzepatide 5 mg and 10 mg (ESM Table 3)

Consequently, it is impossible to determine whether IN GHK-Cu restored the aged hippocampus to a younger baseline, or if it simply pushed the tissue into a novel, alternative compensatory state that functions better in a spatial maze